An Assortment of Journal Abstracts to Enhance Oncology Care : Oncology Times
An abstract is unavailable.
An abstract is unavailable.
An abstract is unavailable.
Yuan Yuan, MD, PhD, discusses post-CDK4/6 inhibitor treatment options for HR-positive breast cancer and expansions of the definition of HER2 expression.
We speak to Herbert Loong, Clinical Associate Professor, the Chinese University of Hong Kong
Isabel Preeshagul, DO, MBS, discusses ongoing efforts to expand treatment options for patients with extensive- or limited-stage small cell lung cancer.
Gotistobart plus pembrolizumab demonstrated antitumor activity and a manageable safety profile in platinum-resistant ovarian cancer.
Multiple Myeloma & CAR-T Cell Therapy Multiple Myeloma & CAR-T Cell Therapy Saad Usmani, MD, MBA, FACP Hematologic Oncologist Chief, Myeloma Service Memorial Sloan Kettering…
Two potentially practice-changing studies published this month in the New England Journal of Medicine showcase the biostatistical expertise at the SWOG Statistics and Data Management…
Prices are based on membership status. Once logged in, the correct registration rate will automatically populate. Registration Type Early Bird Price (October 7, 2024 –…
Illuccix has been approved in Canada for the selection of patients with mCRPC eligible for treatment with PSMA1-targeted radionuclide therapy.
Andrew Chapman and Kuang-Yi Wen of Thomas Jefferson University were named scientific awardees for their work in geriatric oncology research.